Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
Exelixis (NASDAQ: EXEL) has announced its participation in two major healthcare investor conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York City on December 3 at 8:30 a.m. ET, and at the Citi 2024 Global Healthcare Conference in Miami on December 4 at 1:45 p.m. ET. Both fireside chats will be accessible via webcast on www.exelixis.com under the Investors & News section, with replays available for at least 30 days after the events.
Exelixis (NASDAQ: EXEL) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario questo dicembre. L'azienda presenterà alla 36ª Conferenza Sanitaria Annuale di Piper Sandler a New York City il 3 dicembre alle 8:30 ET, e alla Conferenza Sanitaria Globale Citi 2024 a Miami il 4 dicembre alle 13:45 ET. Entrambi gli interventi saranno accessibili tramite webcast su www.exelixis.com nella sezione Investitori & Notizie, con le registrazioni disponibili per almeno 30 giorni dopo gli eventi.
Exelixis (NASDAQ: EXEL) ha anunciado su participación en dos importantes conferencias de inversores en el sector salud este diciembre. La compañía presentará en la 36ª Conferencia Anual de Salud de Piper Sandler en la ciudad de Nueva York el 3 de diciembre a las 8:30 a.m. ET, y en la Conferencia Global de Salud Citi 2024 en Miami el 4 de diciembre a la 1:45 p.m. ET. Ambas charlas se podrán seguir por webcast en www.exelixis.com en la sección Inversores y Noticias, con repeticiones disponibles durante al menos 30 días después de los eventos.
Exelixis (NASDAQ: EXEL)는 이번 12월에 두 개의 주요 헬스케어 투자자 회의에 참여한다고 발표했습니다. 이 회사는 12월 3일 오전 8시 30분 ET에 뉴욕시에서 열리는 Piper Sandler 제36회 연례 헬스케어 회의와 12월 4일 오후 1시 45분 ET에 마이애미에서 열리는 Citi 2024 글로벌 헬스케어 회의에서 발표할 예정입니다. 두 개의 화상 채팅은 www.exelixis.com의 투자자 및 뉴스 섹션에서 웹캐스트를 통해 접근할 수 있으며, 이벤트 후 최소 30일 동안 재생할 수 있습니다.
Exelixis (NASDAQ: EXEL) a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé ce décembre. L'entreprise présentera à la 36e Conférence Annuelle de la Santé de Piper Sandler à New York le 3 décembre à 8h30 ET, et à la Conférence Mondiale de la Santé Citi 2024 à Miami le 4 décembre à 13h45 ET. Les deux discussions seront accessibles en webcast sur www.exelixis.com dans la section Investisseurs & Actualités, avec des rediffusions disponibles pendant au moins 30 jours après les événements.
Exelixis (NASDAQ: EXEL) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitswesen für diesen Dezember angekündigt. Das Unternehmen wird am 3. Dezember um 8:30 Uhr ET auf der 36. jährlichen Gesundheitskonferenz von Piper Sandler in New York City und am 4. Dezember um 13:45 Uhr ET auf der Citi 2024 globalen Gesundheitskonferenz in Miami präsentieren. Beide Veranstaltungen werden über einen Webcast auf www.exelixis.com im Bereich Investoren & Nachrichten zugänglich sein, mit Aufzeichnungen, die mindestens 30 Tage nach den Events verfügbar sind.
- None.
- None.
-- Presentations to be webcast on www.exelixis.com --
-
Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in
New York City . -
Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in
Miami .
To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are registered
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126763789/en/
Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
FAQ
When is Exelixis (EXEL) presenting at the Piper Sandler Healthcare Conference?
What time is Exelixis (EXEL) presenting at the Citi 2024 Global Healthcare Conference?